TOKYO–(BUSINESS WIRE)–Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)
info@solasia.co.jp
Key takeaways:The al qadsiah vs al-hilal fixture between Al-Qadisiyah FC and Al-Hilal Saudi FC is…
Key takeaways:The Bengaluru-Mumbai Vande Bharat Sleeper launch is expected next month, according to NDTV, with…
Key takeaways:Shukra Pradosh Vrat Katha is the Puranic story of Danik, a wealthy man whose…
Key takeaways:Sumit Nagal is India's top-ranked men's singles tennis player, competing regularly across the ATP…
Key takeaways:Official live streaming options and broadcast channels for Al-Faisaly vs Al-Nassr are available through…
Key takeaways:Day one of the 2026 US Grand Prix was reported, but no specific Bottas…